Trial Profile

A Phase I/II Study Evaluating the Safety, Tolerability, Pharmacokinetics and Anti-Tumor Activity of TRS005 in Combination With Cyclophosphamide, Doxorubicin, and PrednisoneT-CHP in Previously Untreated Patients With CD20-positive DLBCL

Status: Not yet recruiting

Phase of Trial: Phase I/II

Latest Information Update: 02 Jul 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cyclophosphamide (Primary) ; Doxorubicin (Primary) ; Prednisone (Primary) ; TRS 005 (Primary)
Indications Diffuse large B cell lymphoma
Focus Adverse reactions
Sponsors Zhejiang Teruisi Pharmaceutical

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com